Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial

B. Calmels (1) , R. Devillier , S. Guia (2) , B. Mfarrej , S. Furst , S. Harbi , A. Granata , C. Faucher (3) , F. Izadifar , B. Makni , O. Vicari , P. Lignee , C. Lemarie , C. Fauriat , D. Olive , Eric Vivier (2) , C. Chabannon , Sophie Ugolini (2) , D. Blaise

1 IPC - Institut Paoli-Calmettes
2 CIML - Centre d'Immunologie de Marseille - Luminy
3 Unité de Transplantation et de Thérapie Cellulaire

Domaines: Immunologie

B. Calmels, R. Devillier, S. Guia, B. Mfarrej, S. Furst, et al.. Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial. Bone Marrow Transplantation, 2017, July 2017 supplement, 52, pp.S155. ⟨10.1038/bmt.2017.134⟩. ⟨hal-01996162⟩